Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon for treating congenital hyperinsulinism. In addition, the company developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.
Metrics to compare | ZELA | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipZELAPeersSector | |
|---|---|---|---|---|
P/E Ratio | 3.3x | 17.1x | −0.5x | |
PEG Ratio | 0.01 | −0.05 | 0.00 | |
Price / Book | 1.4x | 5.4x | 2.6x | |
Price / LTM Sales | 2.3x | 4.6x | 3.2x | |
Upside (Analyst Target) | 66.7% | 22.2% | 47.6% | |
Fair Value Upside | Unlock | 14.0% | 6.1% | Unlock |